TY - JOUR
T1 - SOMATOSTATIN‐REDUCED PROLIFERATION OF MURINE APLASTIC CARCINOMA CONDITIONED TO DIABETES
AU - Vuk‐Pavlović, S.
AU - Božikov, V.
AU - Pavelić, K.
PY - 1982/6/15
Y1 - 1982/6/15
N2 - Murine mammary aplastic carcinoma, when it is passed from one alloxan‐diabetic animal to another, after several passages becomes conditioned to hypoinsulinemia by secreting its own substances(s) immunologically cross‐reactive with insulin (SICRI). Although not cytotoxic, the total daily dose of 2.5 mg of synthetic linear somatostatin per one kg body mass, administered in three or more portions, retards tumor growth in normoinsulinemic mice and the proliferation of tumors preconditioned by three serial passages in diabetics. After the first passage, somatostatin treatment has no effect on the already slow growth of the unconditioned tumor. Somatostatin‐reduced tumor proliferation is accompanied by the strong suppression of insulin and SICRI levels, respectively; this effect is completely abolished by the administration of modest doses of crystalline insulin. It is concluded that somatostatin retards tumor growth by diminution of plasma levels of insulin and SICRI, respectively.
AB - Murine mammary aplastic carcinoma, when it is passed from one alloxan‐diabetic animal to another, after several passages becomes conditioned to hypoinsulinemia by secreting its own substances(s) immunologically cross‐reactive with insulin (SICRI). Although not cytotoxic, the total daily dose of 2.5 mg of synthetic linear somatostatin per one kg body mass, administered in three or more portions, retards tumor growth in normoinsulinemic mice and the proliferation of tumors preconditioned by three serial passages in diabetics. After the first passage, somatostatin treatment has no effect on the already slow growth of the unconditioned tumor. Somatostatin‐reduced tumor proliferation is accompanied by the strong suppression of insulin and SICRI levels, respectively; this effect is completely abolished by the administration of modest doses of crystalline insulin. It is concluded that somatostatin retards tumor growth by diminution of plasma levels of insulin and SICRI, respectively.
UR - http://www.scopus.com/inward/record.url?scp=0019945687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019945687&partnerID=8YFLogxK
U2 - 10.1002/ijc.2910290614
DO - 10.1002/ijc.2910290614
M3 - Article
C2 - 6125480
AN - SCOPUS:0019945687
SN - 0020-7136
VL - 29
SP - 683
EP - 686
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 6
ER -